Therapeutics

T3D-959

Overview

Name: T3D-959
Synonyms: DB959
Therapy Type: Small Molecule (timeline)
Target Type: Other (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2)
Company: T3D Therapeutics, Inc.

Background

T3D-959 is a dual agonist of the peroxisome proliferator activated nuclear receptor delta/gamma, aka PPARδ/γ. It is being developed as an oral therapy for Alzheimer’s disease. In 2013, T3D Therapeutics acquired this compound from DARA BioSciences. In 2010 and 2011, DARA BioSciences had tested DB959 in Phase 1 trials for dyslipidemia and Type 2 diabetes, but subsequently shifted its focus to oncology care products.

The PPAR family of proteins helps regulate blood sugar and triglyceride levels. PPAR activation affects these measures by boosting insulin sensitivity, and this approach has become a mainstay for correcting insulin resistance in diabetes therapy. The rationale for evaluating PPAR agonists in Alzheimer's is based on the hypothesis that sporadic AD is fundamentally an age-related metabolic disease, sometimes called Type 3 diabetes (Sep 2006 conference newsde la Monte and Tong, 2014). Unlike other PPAR-targeted diabetes drugs that have been evaluated in Alzheimer's previously, T3D-959 is not a thiazolidinedione.

The peer-reviewed literature contains three preclinical research reports on T3D-959, by scientists affiliated with T3D Therapeutics. Two report treatment benefits on spatial navigation, memory, and motor performance in rats previously injected with streptozotocin, a pancreatic cancer chemotherapy that poisons insulin-producing beta cells and is used to model diabetes in rodents (Tong et al., 2016Tong et al., 2016). Another paper reports that T3D-0959 normalized streptozotocin-induced changes in the biomarkers pTau, AβPP, Aβ42, ubiquitin, SNAP-25, synaptophysin, IGF-1 receptor (R), IRS-1, Akt, p70S6K, mTOR, and S9-GSK-3β, also in rats (de la Monte et al., 2017).

Findings

In July 2015, a Phase 1/2 study enrolled 36 people with mild to moderate Alzheimer's disease to compare a two-week course of either 3, 10, 30, or 90 mg of T3D-959, taken once daily. This trial did not have a placebo group. It was a biomarker proof-of-mechanism study, in that the primary outcomes were change from baseline of cerebral glucose metabolism as measured by FDG-PET, and change from baseline of functional connectivity between the precuneus/posterior cingulate cortex and hippocampus as measured by resting-state fMRI. The Digit Symbol Substitution Test, ApoE subgroup analysis, blood lipid metabolomics, and ADAS-Cog 11 constituted secondary outcomes. Conducted in Florida and South Carolina, this trial completed in June 2016.

At the 2018 AAIC conference, T3D Therapeutics presented findings from this trial, reporting that T3D-959 was well-tolerated and dose-dependently lowered fasting blood glucose. Metabolomic changes indicated a reduction in insulin resistance. ApoE-negative participants on the three lower doses improved significantly on the ADAS-Cog11, as did ApoE-positive participants on the 30 mg dose. FDG-PET signal reportedly increased on drug, with the largest change for the two highest doses.

In May 2019, the company announced it receieved NIA funding to begin a Phase 2 study called PIONEER (Prospective therapy to Inhibit and Overcome Alzheimer’s Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration). Starting in 2020, the trial is expected to enroll 252 people with mild to moderate AD to evaluate a six-month course of one of three doses of T3D-959 or placebo (see company press release).

Last Updated: 17 Jun 2019

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. Madrid: Highs and Lows of The Insulin Connection

Paper Citations

  1. . Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol. 2014 Apr 15;88(4):548-59. Epub 2013 Dec 28 PubMed.
  2. . T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38. PubMed.
  3. . Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism. 2016 Jun;6(3) Epub 2016 Jun 3 PubMed.
  4. . Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. J Alzheimers Dis. 2017;55(2):849-864. PubMed.

External Citations

  1. company press release

Further Reading

No Available Further Reading